Cortexyme
Company developing new therapies for neurodegenerative diseases.
Cortexyme is a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat what we believe to be a key underlying cause of Alzheimer’s and other degenerative diseases. Cortexyme is targeting a specific pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Cortexyme’s lead small molecule, COR388, has advanced through preclinical and Phase Ib testing and is currently the subject of a Phase 2/3 GAIN clinical trial in mild to moderate Alzheimer’s disease patients.
Visit website: https://www.cortexyme.com/
Details last updated 29-Nov-2019
Cortexyme News
A new drug against Alzheimer's targets gum disease bacteria
New Scientist - 17-Jul-2019
A different approach to Alzheimer's that may be correct
Read more...Bacteria causing gum disease may play a role in triggering Alzheimer's
NHS - 24-Jan-2019
Keeping your gum healthy may save you from Alzheimer's disease
Read more...